Showing results (1591-1600 of 1,836) with videos related to

Sort By:
Pageof 184
Signal Transduction and Targeted Therapy|May 20, 2026
Lactate metabolism and lactylation in cancer: from pathogenesis to therapeutic advancesChunyao Fang, Suiqing Zhou, Kai Yu, et al.
Signal Transduction and Targeted Therapy|May 22, 2026
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospectsJiaqi Lu, Jing Cui, Jing Dong, et al.
Signal Transduction and Targeted Therapy|May 21, 2026
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trialWenjing Wu, Yaping Yang, Haizhu Chen, et al.
Signal Transduction and Targeted Therapy|May 27, 2026
LISS enables immune evasion of colorectal cancers irrespective of MSI statusQingyu Lin, Xingwen Wang, Weixu Zhao, et al.
Signal Transduction and Targeted Therapy|May 27, 2026
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapyFrederik E Deiman, Nils Bömer, Pia Davidsson, et al.
Signal Transduction and Targeted Therapy|May 17, 2026
Targeting EHMT2 overcomes 5-fluorouracil resistance in colorectal cancer by modulating cell cycle and apoptosisIn Hwan Tae, Yunsang Kang, Jinkwon Lee, et al.
Signal Transduction and Targeted Therapy|June 5, 2026
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitorsChaitra Rai, Hang Ruan, Xue Li, et al.
Signal Transduction and Targeted Therapy|June 8, 2026
Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseasesAnkush Borlepawar, Marco Neu, Ziqi Ma, et al.
Signal Transduction and Targeted Therapy|April 14, 2026
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancerBenoist Chibaudel, Louis-Marie Dourthe, Thierry André, et al.
Signal Transduction and Targeted Therapy|April 16, 2026
mTOR-driven integrin β4-enriched extracellular vesicles from lenvatinib-resistant hepatocellular carcinoma fuel lung metastasis via fibroblast-niche formationTiantian Zou, Xufeng Wang, Haoting Sun, et al.
Pageof 184